An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently ...

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

The FDA approved a prefilled syringe format for Ani's purified Cortrophin Gel that should ease administration for MS patients ...

Many people who have struggled with their weight have been told to “eat less and move more.” Others have spent years juggling ...

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...